1-3 of 3
Ferry Lalezari
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract P1-07-30: Phase II adaptive TONIC2 trial to dissect immunomodulatory capacity of doxorubicin or cisplatin induction followed by anti-PD1 in mTNBC

Free
Marleen Kok, Veerle Geurts, Olga Isaeva, Manon de Graaf, Sara Balduzzi, Leonie Voorwerk, Ferry Lalezari, Michiel de Maaker, Nina Abbott, Iris Nederlof, Noah Greenwald, Thomas van Brussel, Mi He, Elisa Champanhet, Maksim Chelushkin, Ingrid Mandjes, Martine Heuver-Mes, Koen van de Vijver, Inge Kemper, Roberto Salgado, Hugo Horlings, Ton Schumacher, Lodewyk Wessels, Diether Lambrechts, Michael Angelo, Marleen Kok
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (12_Supplement): P1-07-30.
https://doi.org/10.1158/1557-3265.SABCS24-P1-07-30
Published: 13 June 2025
View articletitled, Abstract P1-07-30: Phase II adaptive TONIC2 trial to dissect immunomodulatory capacity of doxorubicin or cisplatin induction followed by anti-PD1 in mTNBC
Journal Articles

PD-1T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC

Open Access
Karlijn Hummelink, Vincent van der Noort, Mirte Muller, Robert D. Schouten, Ferry Lalezari, Dennis Peters, Willemijn S.M.E. Theelen, Viktor H. Koelzer, Kirsten D. Mertz, Alfred Zippelius, Michel M. van den Heuvel, Annegien Broeks, John B.A.G. Haanen, Ton N. Schumacher, Gerrit A. Meijer, Egbert F. Smit, Kim Monkhorst, Daniela S. Thommen
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (22): 4893–4906.
https://doi.org/10.1158/1078-0432.CCR-22-0992
Published: 14 November 2022
View articletitled, PD-1T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC
Open the PDF for PD-1T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC in another window
Includes: Supplementary data
Journal Articles

Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer

Available to Purchase
Rosemarie de Haan, Michel M. van den Heuvel, Judi van Diessen, Heike M.U. Peulen, Erik van Werkhoven, Adrianus J. de Langen, Ferry Lalezari, Dick Pluim, Manon Verwijs-Janssen, Conchita Vens, Jan H.M. Schellens, Neeltje Steeghs, Marcel Verheij, Baukelien van Triest
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (5): 1256–1266.
https://doi.org/10.1158/1078-0432.CCR-20-2551
Published: 01 March 2021
View articletitled, Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer
Open the PDF for Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer in another window
Includes: Supplementary data